menu
    • menu
    [{"orgOrder":0,"company":"IO Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Peptide","year":"2020","type":"Not Applicable","leadProduct":"Carboplatin","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"IO Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"IO Biotech \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"IO Biotech \/ Not Applicable"},{"orgOrder":0,"company":"IO Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Peptide","year":"2020","type":"Not Applicable","leadProduct":"IO102","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"IO Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"IO Biotech \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"IO Biotech \/ Not Applicable"},{"orgOrder":0,"company":"IO Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Vaccine","year":"2020","type":"Not Applicable","leadProduct":"IO102","moa":"IDO1","graph1":"Oncology","graph2":"Phase III","graph3":"IO Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"IO Biotech \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"IO Biotech \/ Not Applicable"},{"orgOrder":0,"company":"IO Biotech","sponsor":"HBM Healthcare Investment","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"DENMARK","productType":"Vaccine","year":"2021","type":"Series B Financing","leadProduct":"IO102","moa":"IDO1","graph1":"Oncology","graph2":"Phase III","graph3":"IO Biotech","amount2":0.14999999999999999,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.14999999999999999,"dosageForm":"Intravenous Infusion","sponsorNew":"IO Biotech \/ HBM Healthcare Investment","highestDevelopmentStatusID":"10","companyTruncated":"IO Biotech \/ HBM Healthcare Investment"},{"orgOrder":0,"company":"IO Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Vaccine","year":"2022","type":"Not Applicable","leadProduct":"IO102","moa":"IDO1","graph1":"Oncology","graph2":"Phase III","graph3":"IO Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"IO Biotech \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"IO Biotech \/ Not Applicable"},{"orgOrder":0,"company":"IO Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Vaccine","year":"2022","type":"Not Applicable","leadProduct":"IO102","moa":"IDO1","graph1":"Oncology","graph2":"Phase III","graph3":"IO Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"IO Biotech \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"IO Biotech \/ Not Applicable"},{"orgOrder":0,"company":"IO Biotech","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"IO102-IO103","moa":"Indoleamine 2,3-dioxygenase","graph1":"Oncology","graph2":"Phase II","graph3":"IO Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"IO Biotech \/ IO Biotech","highestDevelopmentStatusID":"8","companyTruncated":"IO Biotech \/ IO Biotech"},{"orgOrder":0,"company":"IO Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Vaccine","year":"2022","type":"Not Applicable","leadProduct":"IO102","moa":"IDO1","graph1":"Oncology","graph2":"Phase III","graph3":"IO Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"IO Biotech \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"IO Biotech \/ Not Applicable"},{"orgOrder":0,"company":"IO Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Vaccine","year":"2022","type":"Not Applicable","leadProduct":"IO102","moa":"IDO1","graph1":"Oncology","graph2":"Phase III","graph3":"IO Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"IO Biotech \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"IO Biotech \/ Not Applicable"},{"orgOrder":0,"company":"IO Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Vaccine","year":"2022","type":"Not Applicable","leadProduct":"IO102","moa":"IDO1","graph1":"Oncology","graph2":"Phase III","graph3":"IO Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"IO Biotech \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"IO Biotech \/ Not Applicable"},{"orgOrder":0,"company":"IO Biotech","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"DENMARK","productType":"Peptide","year":"2022","type":"Collaboration","leadProduct":"IO102-IO103","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"IO Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"IO Biotech \/ Merck","highestDevelopmentStatusID":"8","companyTruncated":"IO Biotech \/ Merck"},{"orgOrder":0,"company":"IO Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Vaccine","year":"2023","type":"Not Applicable","leadProduct":"IO102","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"IO Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"IO Biotech \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"IO Biotech \/ Not Applicable"},{"orgOrder":0,"company":"IO Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Vaccine","year":"2023","type":"Not Applicable","leadProduct":"IO102","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"IO Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"IO Biotech \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"IO Biotech \/ Not Applicable"},{"orgOrder":0,"company":"IO Biotech","sponsor":"Lundbeckfonden BioCapital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"DENMARK","productType":"Vaccine","year":"2023","type":"Private Placement","leadProduct":"IO102","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"IO Biotech","amount2":0.080000000000000002,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.080000000000000002,"dosageForm":"Injectable\/Injection","sponsorNew":"IO Biotech \/ Lundbeckfonden BioCapital","highestDevelopmentStatusID":"10","companyTruncated":"IO Biotech \/ Lundbeckfonden BioCapital"},{"orgOrder":0,"company":"IO Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Vaccine","year":"2023","type":"Not Applicable","leadProduct":"IO102","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"IO Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"IO Biotech \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"IO Biotech \/ Not Applicable"},{"orgOrder":0,"company":"IO Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Vaccine","year":"2023","type":"Not Applicable","leadProduct":"IO102","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"IO Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"IO Biotech \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"IO Biotech \/ Not Applicable"},{"orgOrder":0,"company":"IO Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"DENMARK","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"IRX4204","moa":"","graph1":"Neurology","graph2":"Phase I","graph3":"IO Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"IO Biotech \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"IO Biotech \/ Not Applicable"},{"orgOrder":0,"company":"IO Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"DENMARK","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"IRX4204","moa":"","graph1":"Neurology","graph2":"Phase I","graph3":"IO Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"IO Biotech \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"IO Biotech \/ Not Applicable"},{"orgOrder":0,"company":"IO Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Vaccine","year":"2024","type":"Not Applicable","leadProduct":"IO102","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"IO Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"IO Biotech \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"IO Biotech \/ Not Applicable"},{"orgOrder":0,"company":"IO Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Vaccine","year":"2024","type":"Not Applicable","leadProduct":"IO102","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"IO Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"IO Biotech \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"IO Biotech \/ Not Applicable"},{"orgOrder":0,"company":"IO Biotech","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Vaccine","year":"2024","type":"Not Applicable","leadProduct":"IO102","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"IO Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"IO Biotech \/ Merck & Co","highestDevelopmentStatusID":"10","companyTruncated":"IO Biotech \/ Merck & Co"},{"orgOrder":0,"company":"IO Biotech","sponsor":"EIB","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Vaccine","year":"2024","type":"Financing","leadProduct":"IO102","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"IO Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"IO Biotech \/ EIB","highestDevelopmentStatusID":"10","companyTruncated":"IO Biotech \/ EIB"},{"orgOrder":0,"company":"IO Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Vaccine","year":"2025","type":"Inapplicable","leadProduct":"IO102","moa":"||IDO1","graph1":"Oncology","graph2":"Phase III","graph3":"IO Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"IO Biotech \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"IO Biotech \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals by IO Biotech

    Menu

    IO Biotech

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            IO Biotech

                            Denmark arrow
                            RNA Therapeutics
                            Not Confirmed

                            IO Biotech

                            Denmark arrow
                            RNA Therapeutics
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : IO102,IO103,Pembrolizumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            IO Biotech Completes Phase 2 Enrollment for IO102-IO103 Cancer Vaccine

                            Details : IO102-IO103 is an off-the-shelf, cancer vaccine, kills both tumor cells and immune-suppressive cells. It is being evaluated for resectable melanoma or head and neck cancer.

                            Product Name : IO102-IO103

                            Product Type : Vaccine

                            Upfront Cash : Inapplicable

                            January 09, 2025

                            Lead Product(s) : IO102,IO103,Pembrolizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            IO Biotech

                            Denmark arrow
                            BIO CEO & Investor
                            Not Confirmed

                            IO Biotech

                            Denmark arrow
                            BIO CEO & Investor
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : IO102,IO103,Pembrolizumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : EIB

                            Deal Size : Undisclosed

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            IO Biotech Secures Up to €57.5 million in Debt Financing from The European Investment Bank

                            Details : The financing aims to advance the clinical development of the company's lead product IO102-IO103 an immune-modulatory, off-the-shelf therapeutic cancer vaccine for resectable melanoma.

                            Product Name : IO102-IO103

                            Product Type : Vaccine

                            Upfront Cash : Undisclosed

                            December 20, 2024

                            Lead Product(s) : IO102,IO103,Pembrolizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : EIB

                            Deal Size : Undisclosed

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            IO Biotech

                            Denmark arrow
                            RNA Therapeutics
                            Not Confirmed

                            IO Biotech

                            Denmark arrow
                            RNA Therapeutics
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : IO102,IO103,Pembrolizumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Merck & Co

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            IO Biotech IO102-IO103 with KEYTRUDA® Shows Promising Cancer Vaccine Results

                            Details : IO102-IO103 is an off-the-shelf, cancer vaccine, kills both tumor cells and immune-suppressive cells. It is being evaluated in combination with keytruda for metastatic non-small cell lung cancer.

                            Product Name : IO102-IO103

                            Product Type : Vaccine

                            Upfront Cash : Not Applicable

                            November 07, 2024

                            Lead Product(s) : IO102,IO103,Pembrolizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Merck & Co

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            IO Biotech

                            Denmark arrow
                            BIO CEO & Investor
                            Not Confirmed

                            IO Biotech

                            Denmark arrow
                            BIO CEO & Investor
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : IO102,IO103,Pembrolizumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            IO Biotech Reports Positive Results from Ph 2 Trial of IO102-IO103 in Head and Neck Cancer

                            Details : IO102-IO103 is an off-the-shelf, cancer vaccine designed to kill both tumor cells and immune-suppressive cells. It is being evaluated for squamous cell carcinoma of the head and neck.

                            Product Name : IO102-IO103

                            Product Type : Vaccine

                            Upfront Cash : Not Applicable

                            September 14, 2024

                            Lead Product(s) : IO102,IO103,Pembrolizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            IO Biotech

                            Denmark arrow
                            RNA Therapeutics
                            Not Confirmed

                            IO Biotech

                            Denmark arrow
                            RNA Therapeutics
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : IO102,IO103,Pembrolizumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            IO Biotech Updates on Phase 3 IO102-IO103 Trial with KEYTRUDA® in Melanoma

                            Details : IO102-IO103 is an cancer vaccine designed to kill both tumor cells and immune-suppressive cells. It is being investigated in combination with pembrolizumab for the treatment of resectable melanoma.

                            Product Name : IO102-IO103

                            Product Type : Vaccine

                            Upfront Cash : Not Applicable

                            August 30, 2024

                            Lead Product(s) : IO102,IO103,Pembrolizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            IO Biotech

                            Denmark arrow
                            BIO CEO & Investor
                            Not Confirmed

                            IO Biotech

                            Denmark arrow
                            BIO CEO & Investor
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : IRX4204

                            Therapeutic Area : Neurology

                            Study Phase : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Io Therapeutics Presents IRX4204 Results for ALS Treatment

                            Details : IRX4204 is the company’s phase II clinical development stage, highly selective RXR nuclear receptor agonist compound, supporting its potential use for treatment of amyotrophic lateral sclerosis (ALS).

                            Product Name : IRX4204

                            Product Type : Small molecule

                            Upfront Cash : Not Applicable

                            July 16, 2024

                            Lead Product(s) : IRX4204

                            Therapeutic Area : Neurology

                            Highest Development Status : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            IO Biotech

                            Denmark arrow
                            RNA Therapeutics
                            Not Confirmed

                            IO Biotech

                            Denmark arrow
                            RNA Therapeutics
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : IRX4204

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Io Therapeutics Presents IRX4204 Data for Aging, Parkinson’s, and Alzheimer’s

                            Details : IRX4204 is a highly potent and highly selective, orally available, third generation RXR agonist compound which IS being tested in early phase clinical trials in patients with Parkinson’s disease

                            Product Name : IRX4204

                            Product Type : Small molecule

                            Upfront Cash : Not Applicable

                            July 09, 2024

                            Lead Product(s) : IRX4204

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            IO Biotech

                            Denmark arrow
                            BIO CEO & Investor
                            Not Confirmed

                            IO Biotech

                            Denmark arrow
                            BIO CEO & Investor
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : IO102,IO103,Pembrolizumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            IO Biotech Announces First Patient Dosed in Phase 2 Neoadjuvant/Adjuvant Solid Tumor Basket Trial

                            Details : IO102-IO103 is an off-the-shelf, cancer vaccine designed to kill both tumor cells and immune-suppressive cells. It is under phase 2 clinial trials in combination with pembrolizumab for the treatment of resectable melanoma or squamous cell carcinoma of th...

                            Product Name : IO102-IO103

                            Product Type : Vaccine

                            Upfront Cash : Not Applicable

                            December 21, 2023

                            Lead Product(s) : IO102,IO103,Pembrolizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            IO Biotech

                            Denmark arrow
                            RNA Therapeutics
                            Not Confirmed

                            IO Biotech

                            Denmark arrow
                            RNA Therapeutics
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : IO102,IO103,Pembrolizumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            IO Biotech Completes Enrollment of 380 Patients in Pivotal Phase 3 Trial in Advanced Melanoma

                            Details : IO102-IO103 is an investigational immune-modulating cancer vaccine designed to target the immunosuppressive mechanisms mediated by the proteins indoleamine 2,3-dioxygenase (IDO) and PD-L1.

                            Product Name : IO102-IO103

                            Product Type : Vaccine

                            Upfront Cash : Not Applicable

                            November 10, 2023

                            Lead Product(s) : IO102,IO103,Pembrolizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            IO Biotech

                            Denmark arrow
                            BIO CEO & Investor
                            Not Confirmed

                            IO Biotech

                            Denmark arrow
                            BIO CEO & Investor
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : IO102,IO103,Pembrolizumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Lundbeckfonden BioCapital

                            Deal Size : $75.0 million

                            Deal Type : Private Placement

                            DEALS_DEV arrow-down

                            IO Biotech, Inc. Announces $75 Million Private Placement Financing

                            Details : The net proceeds will be used for the development of IO102-IO103, an investigational immune-modulating cancer vaccine designed to target the immunosuppressive mechanisms mediated by the proteins indoleamine 2,3-dioxygenase (IDO) and PD-L1.

                            Product Name : IO102-IO103

                            Product Type : Vaccine

                            Upfront Cash : Undisclosed

                            August 07, 2023

                            Lead Product(s) : IO102,IO103,Pembrolizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Lundbeckfonden BioCapital

                            Deal Size : $75.0 million

                            Deal Type : Private Placement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth